Overexpression of chemokine receptor cxcr4 in cancer specimens predicts outcome in patients with triple-negative breast cancer

Holm, Neal; Johnson, Lori; Benjamin, L; Quyen, C.

doi:10.1200/jco.2008.26.15_suppl.11064

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Subsequent studies have suggested that the CXCR4/SDF-1 axis plays a role in the metastasis of many types of tumor cells. Retrospective studies in breast, 47 especially triple negative breast cancer 53 and other cancers including nasopharyngeal 54 and ovarian carcinomas 55 have provided evidence that high expression of the CXCR4 receptor on primary tumor specimens correlates with a poorer clinical outcome. In vitro studies 54,56,57 in various tumor cell lines have shown that inhibition of the CXCR4/SDF-1 chemokine axis results in decreased migration and invasion of these cell lines.…”

Section: Cxcr4 and Sdf-1 Role In Cancermentioning

confidence: 99%

The CXCR4/SDF-1 Chemokine Receptor Axis: A New Target Therapeutic for Non-small Cell Lung Cancer

Otsuka

Bebb

2008

Journal of Thoracic Oncology

View full text Add to dashboard Cite

Chemokines are proinflammatory chemoattractant cytokines that regulate cell trafficking and adhesion. The CXCR4 chemokine receptor and its ligand, stromal cell derived factor (SDF-1), constitute a chemokine/receptor axis that has attracted great interest because of an increasing understanding of its role in cancer, including lung cancer. The CXCR4/SDF-1 complex activates several pathways that mediate chemotaxis, migration and secretion of angiopoietic factors. Neutralization of SDF-1 by anti-SDF-1 or anti-CXCR4 monoclonal antibody in preclinical in vivo studies results in a significant decrease of non-small cell lung cancer metastases. Since anti-SDF-1/CXCR4 strategies have already been developed for use in combating human immunodeficiency virus infections, it is likely that these approaches will be used in clinical trials in non-small cell lung cancer in the very near future.

show abstract

Section: Cxcr4 and Sdf-1 Role In Cancermentioning

confidence: 99%

The CXCR4/SDF-1 Chemokine Receptor Axis: A New Target Therapeutic for Non-small Cell Lung Cancer

Otsuka

Bebb

2008

Journal of Thoracic Oncology

View full text Add to dashboard Cite

show abstract

“…Overexpression of CXCR4 has been associated with poor outcomes in patients with advanced cancer, including breast, head and neck, ovarian, and non-small cell lung cancer (NSCLC), among others [4,[9][10][11][12][13][14]. Increased CXCR4 expression has been associated with nodal and distant metastases, and worse survival in NSCLC patients [7,8,15,16].…”

Section: Introductionmentioning

confidence: 99%

CXCR4 expression in lung carcinogenesis: Evaluating gender-specific differences in survival outcomes based on CXCR4 expression in early stage non-small cell lung cancer patients

et al. 2021

View full text Add to dashboard Cite

Introduction Evidence suggests that the expression of certain cytokine receptors increases with lung cancer evolution. Overexpression of the cytokine receptor CXCR4 is associated with poor outcomes in stage IV non-small cell lung cancer (NSCLC), with shorter survival in females with high CXCR4 expression. This study quantifies CXCR4 expression in early stage disease and evaluates its association with gender-specific recurrence-free (RFS) and overall survival (OS) in resected stage I-III NSCLC patients. Methods Patient characteristics and clinical outcomes were obtained from the Glans-Look Lung Cancer (G-LLC) database for early stage NSCLC patients diagnosed between 2003–2006 at the Tom Baker Cancer Centre (TBCC). CXCR4 expression was quantified on tissue microarrays (TMA). Median RFS and OS were evaluated by gender using Kaplan-Meier analyses. CXCR4 expression and outcome data were analyzed using Cox proportional hazards (PH) and multi-state models (MSM). Results 176 stage I-III NSCLC patients were identified. CXCR4 expression was lower in early stage NSCLC patients, with a mean CXCR4 expression of 1729 (SD 1083) compared to 2640 (SD 1541) in stage IV patients. On Kaplan-Meier, median RFS by gender was similar (male 52.8 months vs. female 54.5 months) as was median OS (male 80.9 months vs. female 89.0 months), and there was no significant difference in RFS (p = 0.60) or OS (p = 0.30) by gender and CXCR4 groups over follow-up. By multivariable analysis, CXCR4 expression was not prognostic for RFS (Hazard Ratio (HR) = 1.00, p = 0.73) or OS (HR = 1.00, p = 0.44), and no gender difference was observed. Conclusions CXCR4 expression increases with stage progression in NSCLC but is not prognostic in early stage NSCLC patients of either gender. Mechanisms by which CXCR4 expression increases during lung carcinogenesis warrant further exploration and testing in clinical trials.

show abstract

Overexpression of chemokine receptor cxcr4 in cancer specimens predicts outcome in patients with triple-negative breast cancer

Cited by 2 publications

References 0 publications

The CXCR4/SDF-1 Chemokine Receptor Axis: A New Target Therapeutic for Non-small Cell Lung Cancer

The CXCR4/SDF-1 Chemokine Receptor Axis: A New Target Therapeutic for Non-small Cell Lung Cancer

CXCR4 expression in lung carcinogenesis: Evaluating gender-specific differences in survival outcomes based on CXCR4 expression in early stage non-small cell lung cancer patients

Contact Info

Product

Resources

About